Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and Multiple Primary Neoplasms

lenalidomide has been researched along with Multiple Primary Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Chen, M; Chen, W; Jiang, Q; Li, T; Liu, Y; Peng, J; Shi, X; Wu, J; Xi, X; Yu, X; Zhang, S; Zhu, Y1
Bouscary, D; Chavarot, N; Karras, A; Lebbe, C; Thervet, E1
Ise, M; Kumagai, K; Sakai, C; Tsujimura, H1
Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W1
Schiffer, CA; Srinivasan, S1

Other Studies

5 other study(ies) available for lenalidomide and Multiple Primary Neoplasms

ArticleYear
Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report.
    Medicine, 2020, Oct-30, Volume: 99, Issue:44

    Topics: Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Examination; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Skin Neoplasms; Transplantation, Autologous; Vincristine

2020
Bortezomib Does Not Prevent the Occurrence of Kaposi's Sarcoma in Patients with Haematological Malignancies: Two Case Reports.
    Acta dermato-venereologica, 2017, Oct-02, Volume: 97, Issue:9

    Topics: Aged; Amyloidosis; Antineoplastic Agents; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Sarcoma, Kaposi; Skin Neoplasms; Thalidomide

2017
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms

2014
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
    Medicine, 2017, Volume: 96, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bortezomib; Humans; Lenalidomide; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Thalidomide; Thoracic Vertebrae; Treatment Outcome

2017
Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
    Leukemia research, 2009, Volume: 33, Issue:4

    Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Thalidomide

2009